
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): July 29, 2015

CollabRx, Inc.

(Exact Name of Registrant as Specified in Charter)

**Delaware
(State or Other Jurisdiction of Incorporation)**

**001-35141
(Commission File Number)**

**68-0370244
(I.R.S. Employer Identification No.)**

**44 Montgomery Street, Suite 800
San Francisco, CA 94104-4811
(Address of Principal Executive Offices)**

**(415) 248-5350
(Registrant's telephone number, including area code)**

**Not Applicable
(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 7.01. REGULATION FD DISCLOSURE

In connection with the contemplated merger transaction (the "Merger") between CollabRx, Inc. ("CollabRx") and Medytox Solutions, Inc. ("Medytox"), CollabRx and Medytox have prepared an investor presentation, a copy of which is attached hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K is being furnished under Item 7.01 and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

This Form 8-K, including the investor presentation, contains "forward-looking statements" within the meaning of the safe harbor provisions of the federal securities laws. These statements are based on CollabRx's expectations and involve risks and uncertainties that could cause CollabRx's actual results to differ materially from those set forth in the statements. These risks are discussed in CollabRx's filings with the Securities and Exchange Commission ("SEC"), including an extensive discussion of these risks in CollabRx's Annual Report on Form 10-K for the fiscal year ended March 31, 2015. Such forward-looking statements speak only as of the date they are made, and CollabRx undertakes no obligation to update or revise any forward-looking statement, except as required by law. If CollabRx does update any forward-looking statement, no inference should be drawn that it will make additional updates with respect to that statement or any other forward-looking statements.

Participants in Solicitation

Medytox, CollabRx, and their respective directors, executive officers, and other employees may be deemed to be participants in the solicitation of proxies from Medytox and CollabRx stockholders with respect to the Merger. Information about Medytox's directors and executive officers is available in Medytox's proxy statement for its Annual Meeting of stockholders to be held on August 6, 2015. Information about CollabRx's directors and executive officers is available in CollabRx's annual report on Form 10-K for the fiscal year ended March 31, 2015. Additional information about the interests of potential participants is included in the registration statement and proxy statement and other materials filed with the Securities and Exchange Commission (the "SEC"). These documents are available free of charge at the SEC's website at www.sec.gov, or by going to Medytox's Investors page on its corporate website at www.medytoxolutionsinc.com or by going to CollabRx's Investors page on its corporate website at www.collabrx.com.

Additional Information

This document does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. CollabRx has filed a registration statement on Form S-4, including a joint proxy statement of CollabRx and Medytox, and other materials with the SEC in connection with the Merger. CollabRx urges investors to read these documents because they contain important information. Investors may obtain free copies of the registration statement and proxy statement, as well as other filed documents containing information about Medytox and CollabRx, at www.sec.gov, the SEC's website or by going to Medytox's Investors page on its corporate website at www.medytoxolutionsinc.com or by going to CollabRx's Investors page on its corporate website at www.collabrx.com."

Item 8.01 Other Events

Presentation

On July 29, 2015, CollabRx and Medytox issued a joint investor presentation regarding the Merger. A copy of the presentation is attached hereto as Exhibit 99.1 and is hereby incorporated into this report by reference.

Item 9.01. Exhibits.

99.1 Investor presentation (Pre-merger)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 29, 2015

COLLABRX, INC.

By: /s/ Thomas R. Mika

Name: Thomas R. Mika

Title: President & Chief Executive Officer

Medyto

Solutions & Services For Medical Providers

 **CollabRx**
Expert Systems for Precision Medicine

Investor Presentation
(Pre-merger)



This presentation includes forward-looking statements about CollabRx's and Medytox Solution's anticipated results that involve risks and uncertainties. Some of the information contained in this presentation, including statements as to industry trends and plans, objectives, expectations and strategy for the combined businesses, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by CollabRx and Medytox with the Securities and Exchange Commission. Neither CollabRx nor Medytox undertakes any obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances, except to the extent required by applicable law or regulation. The potential business combination referenced in this presentation is subject to, among other things, stockholder approvals and other customary conditions. We cannot assure you that the contemplated business combination will be consummated.


CollabRx (NASDAQ: CLRX), Medytox (OTCQB: MMMS), and their respective directors, executive officers, and other employees may be deemed to be participants in the solicitation of proxies from CollabRx and Medytox stockholders with respect to the proposed business combination. Information about CollabRx's directors and executive officers is available in CollabRx's annual report on Form 10-K for the year ended March 31, 2015. Information about Medytox's directors and executive officers is available in Medytox's Proxy Statement for its Annual Meeting of Stockholders to be held on August 6, 2015. Additional information about the interests of potential participants will be included in the registration statement and joint proxy statement and other materials filed with the Securities and Exchange Commission (the "SEC"). These documents are available free of charge at the SEC's website at www.sec.gov, or by going to CollabRx's Investors page on its corporate website at www.collabrx.com or by going to Medytox's Investors page on its corporate website at www.medytoxolutionsinc.com.

This document does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. CollabRx will file a registration statement, including a joint proxy statement of CollabRx and Medytox and a prospectus of CollabRx, and other materials with the SEC in connection with the proposed business combination. **We urge investors to read these documents when they become available because they will contain important information.** Investors will be able to obtain free copies of the registration statement and proxy statement, as well as other filed documents containing information about CollabRx and Medytox, at www.sec.gov, the SEC's website or by going to CollabRx's Investors page on its corporate website at www.collabrx.com or by going to Medytox's Investors page on its corporate website at www.medytoxolutionsinc.com.

- A leading provider of expert-informed clinical decision support systems for diagnostic labs, physicians and patients navigating advanced cancer.

**Genetic Variant Annotation™
(GVA) Service**

Supporting the data interpretation and reporting needs of academic and commercial genetic testing labs



**Therapy Finders®
and CancerRx**

Providing web-based and mobile products for physicians and patients at the point-of-care



- *We address the emerging market for genomic testing in cancer with an industry-leading, scalable solution for evidence-based therapy selection related to actionable biomarkers.*


- A vertically-integrated provider of clinical laboratory testing and business solutions to drug rehab and pain management clinics and to private physician practices nationwide.

Operating five high-complexity, CLIA-certified clinical laboratories in five locations

Name	Location	Services
Biohealth Medical Laboratory	Miami, FL	Screening and clinical
International Technologies	Waldwick, NJ	Screening and clinical
Alethea Laboratories*	Las Cruces, NM	Screening, clinical and confirmations
EPIC	West Palm Beach, FL	Screening and clinical, neurotransmitters, confirmations
Epinex Diagnostics Labs	Tustin, CA	Screening and clinical


*New Mexico labs do not need physician orders and can accept lab orders from individuals.

History of high growth and profitability




- *We have a track record of acquiring and retaining customers by offering cutting-edge technology and systems to automate and improve their internal processes and we seek to expand our service offerings into other testing areas and markets.*

Strategic: *adding to existing test menu, while building an end-to-end solution in cancer testing.*




- Medytox plans to enter testing markets in clinical diagnostics, including cancer and diabetes.
 - Opportunity exists to acquire a genomic testing lab or to develop one internally.
- Medytox lab services customers are currently demanding higher complexity tests that require evidence-based interpretation and therapy selection.
 - Neurotransmitter testing.
 - Pharmacogenomics for dosing and drug tolerance.
- CollabRx has developed a sophisticated platform for evidence-based interpretation and therapy selection in cancer that can also be applied to other disease areas.
- CollabRx is not a lab, but sells services to other labs that perform tests and report results to physicians.
- CollabRx and Medytox together can offer a superior solution for genomic-based clinical diagnostics.

Operational: *offering centralized management and expertise for controlled growth and profit.*




- Medytox maintains a corporate structure that includes key areas of expertise for health care companies, such as:
 - Marketing and Sales
 - Compliance
 - Legal
 - HIPAA-compliant IT
- During 2013 and 2014, Medytox invested in a seasoned senior and middle management team to ensure stability through a period of high growth.
- CollabRx team is dedicated to content acquisition and IT development and has not yet invested in sales and marketing.
- As CollabRx expands, added expertise available from Medytox corporate.
- Ability to eliminate duplicate public company expenses will allow CollabRx to achieve cash positive position faster.

Financial: *building a highly liquid platform on NASDAQ for a broader investor base and access to capital.*




- Medytox has a strong base of revenue and profit in core business of toxicology testing.
- Medytox has a track record of on-boarding capabilities and expertise at low prices and adding substantial value post-acquisition.
- Traded on the OTC as MMMS since 2011, with an intention to up-list to NASDAQ.
- CollabRx focus on product development now transitioning with revenue ramp in second half of 2015.
- CollabRx expense of ~\$1M to maintain stand-alone public company can be deployed to sales and marketing.
- Recent public offerings provide capital for growth (\$7.5M cash as of 3/31/15).
- CollabRx has thousands of shareholders with an average daily trading volume of >114,000 shares (50d avg).

Organic Growth and Diversification





Expert Systems for Precision Medicine



- *Value-added solutions support core lab service business and have independent operations and brands to pursue external growth.*

- Total Market Size – estimated at **\$35 Billion***
- **Large and growing** number of facilities in a **fragmented market**:
 - Between **14,500 to 16,700 outpatient clinics***.
 - Top 50 control less than 20% of the market*.
- Market **growth** from **high demand**:
 - Over 23 million Americans are addicted to alcohol and other drugs**.
 - The number of Americans in addiction treatment ranges from 2.5 million to 4.1 million*** (*approx. 11%-18% of people needing treatment*).
- Insurance coverage and **ACA** expected to **drive** additional **growth**:
 - 3 to 5 million people who have a diagnostic addiction disorder warranting treatment will gain coverage through healthcare reform****.
 - The improving economic environment and the ACA's expansion of private and government coverage of drug and alcohol rehabilitation services will help bolster demand in this industry segment, which should boost revenues*.

**Includes establishments with medical staff who primarily provide outpatient services related to the diagnosis and treatment of substance abuse and other mental health disorders. Not including hospitals and other inpatient care facilities.*

Sources: *IBIS World, **The National Council on Alcoholism and Drug Dependency, ***SAMHSA, ****National Association of Alcoholism and Drug Abuse Counselors

- Total Market Size – estimated at **\$2-\$4 billion***
- **Large and growing** number of clinics in a **fragmented market***:
 - Private clinics in the U.S. estimated between 1,500 to 2,500.
 - More than 6,800 doctors specialize in pain management and more than 600,000 doctors are licensed to prescribe pain medication.
 - Of 1,339 clinics surveyed, 91.2% had one or two doctors, 7.5% had 3 to 4 doctors and 1.3% had more than 4 doctors.
 - Estimated average annual revenues per clinic are \$2.6 million with pre-tax profits of 25%.
- Market **growth** from **high demand**:
 - Chronic pain affects an estimated 100 million Americans, or one-third of the U.S. population.** Approximately 25 million people experience moderate to severe chronic pain with significant pain-related activity limitations and diminished quality of life.*
 - Between **5 to 8 million people use opioids** for long-term pain management.***
 - In 2012, U.S. providers wrote 259 million prescriptions for opioid painkillers.**

Sources: *The U.S. Addiction Rehab Market, Bharat Publication, **NIH, ***CDC and Pain Physician Publication.


- Total Available Market – estimated at **\$14 billion*** (12 million cancer patients in US)
- Current **penetration** for complex, multi-gene Next Generation Sequencing (NGS)-based tests – estimated at **\$1.3 billion****, including equipment sales.
- Major applications in oncology include sequencing for:
 - **Hereditary** genetic mutations that could make a person susceptible to cancer;
 - **Mutations** in a person's normal cells or tumor cells for a deeper understanding of a known cancer;
 - **Monitoring** to assess **for therapeutic response**; and
 - **Monitoring** for **recurrence**.
- Penetration for these applications will increase from ~6%-15% to 26%-65% within 5 years as new cancer diagnoses increase **from 1.7 million annually today to 2+ million in 2020.***
- Today testing is done primarily in specialized reference laboratories and academic medical centers.
 - As reimbursement is clarified, large scale adoption of complex, multi-gene testing by community physicians is expected.

Sources: *American Cancer Society and **Morgan Stanley Research, "The Realities of Clinical Genomics", May 13, 2015 .

- Lab Services:
 - **Drivers** are primarily **secular growth** and attention to physician - patient **compliance**.
 - Largest growth markets for rehab centers are warm weather, coastal states of Florida and California.
 - Physicians are under increasing scrutiny to ensure that their patients are taking pain medications as prescribed.
 - Most states track prescription drug abuse through **statewide monitoring programs** and at **least three states mandate** testing.
 - Increasingly, rehab clinics and pain management centers **require additional value-added services**.
 - These include automation for test ordering and longitudinal tracking, billing services, integration with electronic medical records and cash flow management – all services offered by Medytox.
- Genetic-based Cancer Testing:
 - Drivers are primarily advances in technology that have dramatically **lowered the cost** of multi-gene testing and the discovery of **targeted therapies** as alternatives or adjuncts to chemotherapy and radiation.
 - The use of multi-gene tests has been growing rapidly and will expand once **reimbursement** is available.

(Dollars in Thousands)

Annual Performance since Formation




- Medytox has outperformed its larger competitors and the laboratory testing industry overall in a highly fragmented, technology-driven industry.

Competitor	Ownership	Market Share (%)	Toxicology Revenues 2014 (millions)	2014/2013 Revenue Growth
Alere Toxicology	Private	14%	\$331	(4-5%)
Quest Diagnostics	NYSE: DGX	9%	\$219	+4%
Medytox Solutions	OTCQB: MMMS	2%	\$58	+38%
ALL OTHERS		<75%	\$1,842	+7%
AIT Laboratories	Private	<5%	Unknown	Unknown
Millennium Health	Private	<5%	Unknown	Unknown
PCLS	Private	<5%	Unknown	Unknown

Source: IBISWorld: *Toxicology Laboratories in the US*, March 2015

- Continue to grow core lab business by offering high quality testing, a comprehensive menu, and superior customer service, supported by:
 - Medytox Advantage™ – a proprietary web-based lab ordering and reporting software offering,
 - a national presence with labs and professional sales teams,
 - a centralized customer service team, and
 - a dedicated IT and software development team to eliminate reliance of customers on third-party suppliers.
- Continue implementation of “Dry-Spot” patented technology for self-directed and physician-ordered urine and blood testing (using “pin-prick” amounts of blood).
- Promote diversification of revenue base by cross-selling best-in-class value-added services among existing customers and through sales by independent subsidiaries.
 - ClinLab laboratory information systems, MedicalMime electronic health records, Medical Billing Choices revenue cycle management, and Platinum Financial Services for securitization of high-quality A/R.
- Continue to grow CollabRx informatics business supporting both current neurotransmitter and pharmacogenetics markets and enter cancer testing market.



*At closing, the surviving listed entity will be rebranded as:
Renova Health, Inc., NASDAQ: RNVA.*

Requirement	Current Standard*	Medytox CollabRx
Stockholder's equity	\$5 million	✓
Market value of publicly held shares	\$15 million	✓
Operating history	2 years	✓
Market value of listed securities	\$50 million	✓
Net Income from continuing operations	\$750 thousand	✓
Publicly held shares	1 million	✓
Shareholders (round lot)	300	✓
Market makers	3	✓
Corporate Governance	Yes	✓
Bid Price	\$4	<input type="checkbox"/>

*Strictest standard among the Equity, Market Value of Listed Securities and Net Income Standards for initial listing on the NASDAQ Capital Market.

Seamus Lagan, Chief Executive Officer. Directed the formation of Medytox and its transition from its former business via Alcimed, LLC, a consulting firm he founded in 2007 that specializes in restructuring, development and management of small companies in both the private and public sectors. CEO of the two main subsidiaries of Medytox since their inception in 2011-2012. Private investor. Graduate of Ballymena Technical College, Northern Ireland.

Samuel R. Mitchell, COO, Medytox Solutions, Inc. Has a broad background with extensive knowledge in Healthcare administration. He previously served as COO of Premier Family Health, P.A., a Practice Administrator with Pulmonary Disease Specialist, P.A., the Chief Business Officer for Greenville Clinic Corp. and the Area Director for U.S. Healthworks Medical Group. His career started as Administrative Assistant at the Tallahassee Memorial Hospital in 2001. MBA and MHA from Nova Southeastern University.

Jeffrey Wadman, Interim CFO, Medytox Solutions, Inc. Served 2008-2014 as Chief Accounting Officer at Oxbow Carbon, from 2005-2008 as Global Controller at Steifel Laboratories, prior to that he was Director of Financial Reporting at Eli Lilly and Company. BS in Accounting from Ball State University, IN. Has been a CPA since 1981.

William DePond, MD, COO, Medytox Diagnostics, Inc. Served from 2009-2013 as President & Division CEO of MEDLAB/Laboratory Partners. Has over 20 years' experience in the lab business either as Laboratory Director, Medical Director, Chief Medical Information Officer or Chief Medical Officer. From 1995-2006 he was Associate Medical Director, University of Missouri-Kansas City School of Medicine as well as Vice-Chairman, Department of Pathology and Laboratory Medicine.

Charles Darcy, Director: Compliance, Medytox Solutions, Inc. Served as COO at the Broward County Medical Examiner's Office. Has over 30 years' experience in the Health Care sector. Since 1988 is a licensed Laboratory supervisor in Florida. Bachelor's in Clinical Laboratory Service and MT (ASCP) from University of Lowell, MA and MHA from University of South Florida, Tampa.

Dean M. Viskovich Esq., Director: Legal, Medytox Solutions, Inc., Admitted to the Bar in 1986 in Florida and in 1987 in New York. Served as Managing Attorney, Litigation Department at Vernis & Bowling of Miami, P.A. from 2005 – 2011. BA from State University of New York at Albany and Juris Doctorate from Nova Southeastern University.

Steve Ziemian, Head of Sales of Medytox Medical Marketing & Sales, Regional Business Director of Strativa Pharmaceuticals. Product Manager, Corporate Sales Training Manager, and Institutional Business Manager for Novo Nordisk. Sales Representative for Aventis Pharmaceuticals. Founder and President of Reach Me Daily, a HIPAA-compliant social network serving the long-term care market.

INSIDE DIRECTORS (2):

Thomas R. Mika, *Executive Chairman of Medytox (effective with the merger) and CEO, CollabRx, Inc.*, served from 2005 – 2012 as Chairman & CEO of Tegal Corporation and was its EVP/CFO since 2002. Extensive prior experience in executive management and consulting in health care, software and chain restaurants. BS in Microbiology from the University of Illinois at Urbana-Champaign and MBA from the Harvard Business School.

Seamus Lagan, *CEO* (see Post-merger Management Team)

INDEPENDENT DIRECTORS (5):

Paul R. Billings, MD, PhD, director of CollabRx, Inc. since 2014. Author, lecturer, consultant, professor and thought leader in genomic medicine. Executive-in-Residence at the California Innovation Center of Johnson & Johnson. Former Chief Medical Officer, Thermo Fisher Scientific. Member of FDA Science Board, VA Genomic Medicine Advisory Committee, Institute of Medicine's Genomic Medicine Roundtable. Director of Trovogene. Co-founder of Cordblood Registry. Former Director of Corporate Development, LabCorps, and former Director of Ancestry.com and Omicia.

Christopher E. Diamantis, director of Medytox since 2013. Chairman and Chief Executive Officer of Integrated Financial Settlements, Inc. Director and managing partner of the Gabor Agency, Inc. Former Chairman of Pro Bank Financial Holding Company, the parent of Pro Bank. Director of Esquire Bank, a federally chartered savings bank in New York City. Director and partner in Counsel Financial Services, Inc., a specialty financial firm catering to the needs of the legal community and the largest non-bank lender to law firms. Past member of the Board of Governors of the Florida State University College of Business and past president of the National Structured Settlements Trade Association.

Benjamin Frank, director of Medytox since 2013. Retired lawyer and businessman, with particular experience in healthcare, foreign trade, retail, business development and government. After practicing as an attorney, from 1962 to 1966, he was a Senior Vice President and member of the Board of Directors of Allied Stores Corporation. Former Vice President and Trustee of North Shore University Hospital, currently North Shore University Hospital, Long Island Jewish Hospital System. Appointed in February 2009 by former Florida Governor Charlie Crist to the Board of the Health Care District of Palm Beach County and served as Chair of the Board from 2011 to 2013.

Michael Goldberg - Managing Director of Monarch Capital LLC, a corporate consulting company servicing public and private companies. Formerly Director, Acting Chief Executive Officer and President of IDO Security, Inc., Director and Chief Executive Officer of Rx Medical Services Corp. (RXM), an American Stock Exchange listed company. Prior to his career in corporate restructuring, Mr. Goldberg was a litigator in Philadelphia. He began his career as an Asper Fellow in the US Attorney's office in 1974 with the Criminal division of the Department of Justice in Washington, D.C. (Watergate prosecution team) before becoming an Assistant District Attorney in Philadelphia.

Robert Lee - Mr. Lee is currently Managing Partner of Sheffield Investment Partners. Previously, he was Managing Director of New Stream Capital and Managing Director at CRT Capital Group in Stamford, CT. A Managing Director of Morgan Stanley Dean Witter from 1984 until 2000, Mr. Lee ran several units of Dean Witter's Investment Bank including the M&A Group. Mr. Lee serves on several boards, including SL Investment Management, a UK based, and FSA licensed investment manager, Springs Industries, and Springs Window Fashions. Mr. Lee is also on the Board of Visitors for the Wake Forest Schools of Business, and was its former Chairman. Mr. Lee attended Dartmouth College and the University of Chicago Graduate School of Business.

- Medytox model for organic growth combined with diversification drives current and future company value.
 - Track record of profitable growth and adherence with laws and regulations.
 - Initial revenue diversification realized through sales by wholly-owned subsidiaries.
 - Development and implementation of “Dry-Spot” technology and expansion of self-directed testing in early stages.
 - Additional acquisitions of lab capacity and related services and capabilities identified.
- Addition of CollabRx offers entry to emerging cancer testing market with industry-leading therapy selection and decision-support capabilities.
- Strong management team and expanded sales force put in place within last 12 months to support continued growth.
- Few opportunities to invest in NASDAQ listed growth companies in this sector.
- Value proposition of merger not fully reflected in current CollabRx stock price.

Please contact the following individuals for additional information:

Seamus Lagan, CEO – Medytox Solutions, Inc.
slagan@medytoxsolutionsinc.com

Thomas Mika, CEO – CollabRx, Inc.
tmika@collabrx.com

Investor and Public Relations:

Sebastien Sainsbury, Medytox Solutions, Inc.
ssainsbury@medytoxsolutionsinc.com

www.medytoxolutionsinc.com

www.collabrx.com